Immunoprecise Fundamentals

IPA
 Stock
  

USD 3.84  0.04  1.05%   

Immunoprecise Antibodies fundamentals help investors to digest information that contributes to Immunoprecise Antibodies' financial success or failures. It also enables traders to predict the movement of Immunoprecise Stock. The fundamental analysis module provides a way to measure Immunoprecise Antibodies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunoprecise Antibodies stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh
Immunoprecise Antibodies Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 7.33 Million. The current year Interest Expense is expected to grow to about 596.1 K, whereas Consolidated Income is forecasted to decline to (9.1 M).

Immunoprecise EBITDA Analysis

Immunoprecise Antibodies' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Immunoprecise Antibodies Earnings Before Interest Taxes and Depreciation Amortization EBITDA

(1.76 Million)

Share
EBITDA 
 = 
Revenue 
-  
Basic Expenses 
More About EBITDA | All Equity Analysis

Current Immunoprecise Antibodies EBITDA

    
  (14.06 M)  
Most of Immunoprecise Antibodies' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunoprecise Antibodies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Immunoprecise EBITDA Historical Pattern

Today, most investors in Immunoprecise Antibodies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunoprecise Antibodies' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunoprecise Antibodies ebitda as a starting point in their analysis.
 Immunoprecise Antibodies EBITDA 
Share
      Timeline 
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Compare to competition

Immunoprecise EBITDA Margin

EBITDA Margin

(0.098)

Share
Immunoprecise Antibodies EBITDA Margin is projected to increase slightly based on the last few years of reporting. The past year's EBITDA Margin was at -0.09
According to the company disclosure, Immunoprecise Antibodies reported earnings before interest,tax, depreciation and amortization of (14.06 Million). This is 101.6% lower than that of the Healthcare sector and 114.04% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 100.36% higher than that of the company.

Immunoprecise Antibodies Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immunoprecise Antibodies's current stock value. Our valuation model uses many indicators to compare Immunoprecise Antibodies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunoprecise Antibodies competition to find correlations between indicators driving Immunoprecise Antibodies's intrinsic value. More Info.
Immunoprecise Antibodies is currently regarded as number one stock in cash per share category among related companies. It is currently regarded as number one stock in price to book category among related companies fabricating about  0.85  of Price to Book per Cash per Share. The ratio of Cash per Share to Price to Book for Immunoprecise Antibodies is roughly  1.17 . As of July 1, 2022, Price to Book Value is expected to decline to 3.19. Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunoprecise Antibodies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunoprecise Antibodies' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunoprecise Antibodies' earnings, one of the primary drivers of an investment's value.
Immunoprecise Antibodies is considered the number one company in total debt category among related companies. Total debt of Biotechnology industry is currently estimated at about 17.6 Billion. Immunoprecise Antibodies adds roughly 2.81 Million in total debt claiming only tiny portion of stocks in Biotechnology industry.
Total debt  Workforce  Valuation  Revenue  Capitalization

Immunoprecise Antibodies Institutional Holders

Institutional Holdings refers to the ownership stake in Immunoprecise Antibodies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunoprecise Antibodies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunoprecise Antibodies' value.
Security TypeSharesValue
Ingalls Snyder LlcCommon Shares932.2 K4.8 M
Citadel Advisors LlcCall Options296.6 K1.5 M
Bank Of MontrealCommon Shares140.5 K718 K
Ikarian Capital LlcCommon Shares77.7 K399 K
Bank Of America CorpCommon Shares57.5 K295 K
Susquehanna International Group LlpPut Options36.1 K186 K
Gradient Capital Advisors LlcCommon Shares20 K103 K
Jpmorgan Chase CoCommon Shares19.9 K102 K
Geode Capital Management LlcCommon Shares17.5 K89 K

Immunoprecise Fundamentals

About Immunoprecise Antibodies Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunoprecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunoprecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunoprecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue1.3 M1.3 M
Cost of Revenue7.3 M7.3 M
Revenues20.6 M19.1 M
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunoprecise Antibodies without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Earnings Calls Now

   

Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immunoprecise Antibodies Piotroski F Score and Immunoprecise Antibodies Altman Z Score analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
90.4 M
Quarterly Revenue Growth YOY
0.066
Return On Assets
-0.19
Return On Equity
-0.43
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.